Bio-Path Hldgs Inc Stock Price, News & Analysis

Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced an upcoming poster presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA from April 8-13, 2022. Dr. Maria Gagliardi will present pre-clinical studies of BP1003, a liposomal STAT3 antisense agent, aimed at treating breast and ovarian cancer cells in combination with chemotherapy drugs. The presentation is scheduled for April 12, 2022, from 1:30-5 PM ET, focusing on enhancing treatment efficacy.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a conference call on March 11, 2022, at 8:30 a.m. ET to discuss its financial results for the full year ended December 31, 2021, along with a business overview. The company utilizes its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop targeted cancer drugs. Key products include prexigebersen, in a Phase 2 study for blood cancers, and prexigebersen-A, which has FDA clearance for a Phase 1 study in solid tumors. An IND application for BP1003 is expected in 2022.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced that CEO Peter Nielsen will present at the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10, 2022, at 7:00 a.m. ET. The pre-recorded presentation will be accessible via an audio webcast on Bio-Path's website for 90 days post-event. Bio-Path focuses on developing targeted cancer drugs using its proprietary DNAbilize® RNAi technology. Its lead candidate, prexigebersen (BP1001), is currently in Phase 2 trials for blood cancers, while other products are also in development for various cancers.

Bio-Path Holdings (NASDAQ: BPTH) recently showcased preliminary data at the 2021 ASH Annual Meeting, demonstrating the safety and efficacy of prexigebersen in high-risk AML patients. The Phase 2 study involved patients treated with prexigebersen combined with decitabine and venetoclax. Key outcomes indicated that 50% of patients receiving the prexigebersen + decitabine regimen achieved responses, while 67% of those on the combination therapy with venetoclax reached complete remission. These results are promising for a challenging patient population.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) reported its Q3 2021 financial results, achieving a net loss of $2.1 million, or $0.29 per share, compared to a $3.0 million loss or $0.80 per share in Q3 2020. The company saw a decrease in R&D expenses to $1.0 million from $2.0 million, while G&A expenses rose slightly to $1.1 million. Bio-Path highlighted recent corporate milestones, including FDA clearance for two clinical trials: prexigebersen-A for solid tumors and BP1002 for relapsed AML patients. As of September 30, 2021, the company had $26.6 million in cash.

Bio-Path Holdings (NASDAQ: BPTH) will hold a conference call on November 12, 2021, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021. The company is focused on developing its proprietary DNAbilize^® antisense RNAi nanoparticle technology to treat cancers. Bio-Path's lead candidate, prexigebersen (BP1001), is in a Phase 2 trial targeting blood cancers. It is also developing BP1002 and BP1003, with an IND filing expected in 2022 for BP1003. Access to the call can be made via phone or through a live webcast on the company’s website.

Bio-Path Holdings (BPTH) announced a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. The presentation will feature safety and preliminary efficacy data from the Phase 2 trial of prexigebersen (BP1001), targeting acute myeloid leukemia. Dr. Maro Ohanian from M.D. Anderson Cancer Center will lead the presentation on December 11, detailing the therapy's safety and efficacy in patients with high-risk and relapsed/refractory AML. This event is pivotal for showcasing BPTH's innovative drug development.

Bio-Path Holdings has received FDA clearance for its IND application to start a Phase 1/1b clinical trial of prexigebersen-A targeting solid tumors, including ovarian and triple negative breast cancer. This marks a significant milestone as the company advances its fourth drug candidate into clinical testing. Preclinical trials showed a promising 86% decrease in tumor burden with no toxicity noted in animal studies. The trial will treat patients using a 3+3 design across multiple cancer centers, beginning with six evaluable patients.

Bio-Path Holdings has received FDA clearance for the IND application of BP1002, its second drug candidate, which aims to treat refractory/relapsed acute myeloid leukemia (AML). This Phase 1/1b clinical trial will evaluate BP1002's efficacy targeting the Bcl-2 protein. The trial is expected to involve several leading cancer centers, starting with six evaluable patients. Preclinical studies suggest BP1002 combined with decitabine may benefit patients resistant to current therapies. The study’s design includes a 3+3 model, with a starting dose of 20 mg/m² administered twice weekly.